Navigation Links
Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured''

WASHINGTON--(BUSINESS WIRE)--May 21, 2007 - Results from a new study, presented at the 38th annual Digestive Disease Week (DDW) conference, showed that more than 99 percent of patients with chronic hepatitis C virus (HCV) infection who were treated successfully with PEGASYS(R) (peginterferon alfa-2a) had no detectable virus up to seven years later - validating the use of the word "cured" to describe these patients, according to study authors. Currently, the best indicator of treatment success is a sustained viral response (SVR), defined as undetectable hepatitis C virus in the blood six months after the end of treatment. The results announced today are from a long-term follow-up study to determine whether the virus re-emerges in patients who achieve an SVR. (Studies show that, overall, about half of patients with hepatitis C monoinfection can achieve an SVR with PEGASYS and ribavirin treatment, the current standard of care.)

"The results announced today are encouraging because it is rare in the treatment of life-threatening viral diseases that can we tell patients they have the chance for a cure," said Dr. Mitchell L. Shiffman, Professor of Medicine, Chief of Hepatology and Medical Director of the Liver Transplant Program, Virginia Commonwealth University Medical Center, and study author. "But in hepatitis C today, we are able to help some patients achieve an outcome that effectively enables them to put their disease behind them."

About the Study (Abstract ID #444)

This study monitored 997 patients (either mono-infected with chronic HCV or co-infected HCV and HIV) who achieved an SVR following treatment with PEGASYS monotherapy or combination therapy with PEGASYS and ribavirin. Serum levels of HCV were monitored on an annual basis for an average of 4.1 years (range 0.4 to 7 years) following successful treatment. Of the 997 patients, 989 (greater than 99 percent) maintained undetectable levels of H
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:8/27/2014)... Aug. 27, 2014 Ambit Biosciences (Nasdaq: AMBI ... drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, ... Care Conference to be held at The New York Palace ... September 3-4, 2014. Alan Fuhrman , Ambit,s ... lead drug candidate, quizartinib, at 1:10 p.m. ET on Wednesday, ...
(Date:8/27/2014)... -- After the February 2014 launch of their new ... medical practices and management companies, Prime Clinical is reporting ... "The feedback has been great," says Director of ... of demos and new sign-ups is a reflection of ... of software features." Prime Clinical developed ...
(Date:8/27/2014)... 27, 2014  Zimmer Holdings, Inc. (NYSE and SIX: ... it will be participating in the Morgan Stanley 2014 ... New York, New York , on Tuesday, ... CEO of Zimmer, will be presenting at 9:10 a.m. ... of Biomet, will join Mr. Dvorak for the Q&A ...
Breaking Medicine Technology:Ambit Announces Participation At Baird 2014 Health Care Conference 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3
(Date:8/27/2014)... The American Brain Tumor Association ... 2014-2016 Basic Research Fellowships and 2014-2015 Discovery Grant Awards. ... is seeding the field with talented, bright young investigators ... the causes, effects, diagnosis and treatment of brain tumors. ... based on the potential to advance the understanding and ...
(Date:8/27/2014)... the onset of a cancer defense mechanism known ... Cancer Center are leveraging it in a new ... cell death rather than survival. The novel treatment ... referred to as the "Trash Man" due to ... autophagy. Results from preclinical experiments suggest this experimental ...
(Date:8/27/2014)... Cash House 's contributions to Horizons ... upkeep of the shelter including new initiatives and a wide ... the lives of each youth who walk through their door. ... for youth ages 16-25. Not only does Horizons operate as ... for the youth who come through their doors. Horizons has ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 IQ ... supplements, today announced its continued support of the Cystic ... Formulations participated in a fundraising campaign led by TigerFitness.com ... of IQ Formulations’ sales were donated to the respected ... to a TigerFitness.com fundraiser to support Isla, a young ...
(Date:8/27/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND REGENERATIVE PRODUCTS , the global market for advanced ... by 2014-end to $42.2 billion by 2019, with a ... to 2019. New technologies and an increasingly older population ... market. , While there are many conventional and generally ...
Breaking Medicine News(10 mins):Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Promising new cancer therapy uses molecular 'Trash Man' to exploit a common cancer defense 2Health News:Cash House a Major Supporter of Horizons for Youth 2Health News:Cash House a Major Supporter of Horizons for Youth 3Health News:IQ Formulations Contributes Sizeable Donation to Cystic Fibrosis Foundation 2Health News:Global Market for Advanced Orthopedic Technology to Reach $42.2 Billion in 2019; Biotechnological Advancements Driving the Market 2Health News:Global Market for Advanced Orthopedic Technology to Reach $42.2 Billion in 2019; Biotechnological Advancements Driving the Market 3
... study report based on detainee interrogations finds that ... not involve physical pain—such as psychological// manipulation, deprivation, ... much mental distress and traumatic stress as physical ... torture encompass both physical and mental pain and ...
... that nearly four out of five hospitalized children receive ... adults//. The authors fear that treating children with off-label ... the magnitude of off-label use of drugs in children," ... specializing in infectious diseases at The Children’s Hospital of ...
... been a success, but continued commitment from the government is ... officials. ,The Immunization Plus Days (IPDs) initiative was ... (NPI) ¯ a government initiative with support from UNICEF and ... 18 northern regions still affected by the virus. ...
... Scientists have developed a test for the early diagnosis of lung ... and off in cells// lining the airways leading to the lungs ... effective. ,Lung cancer is the most deadly form of ... men and the third most common in women. In 2002 about ...
... University researchers have released results of a study showing ... intake//, higher body weight, a decrease in calcium and ... ,The report also noted that studies funded ... show detrimental effects from soft drinks than studies that ...
... the accurate amount of fat in a human body, according// to ... for measuring the amount of fat in a person's body. It ... of their height. ,Generally, a BMI of 25 or ... A person with a higher BMI is thought to be at ...
Cached Medicine News:Health News:All Forms of Ill Treatment Cause Post Traumatic Stress Disorder-PTSD 2Health News:All Forms of Ill Treatment Cause Post Traumatic Stress Disorder-PTSD 3Health News:Prescribing Off Label Drugs for Children may Be Hazardous 2Health News:Prescribing Off Label Drugs for Children may Be Hazardous 3Health News:Nigerian Programme Increases Polio Immunisation 2Health News:Gene Cell Test may Aid Early Lung Cancer Diagnosis 2Health News:Yale Researchers Weigh the Science on Soft Drinks and Health 2
For the quantitative determination of Gamma Glutamyltransferase in serum or plasma...
The CK method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase activity in serum and plasma...
The XCHO method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of cholesterol in serum and plasma....
For the quantitative in vitro determination of Cholesterol in serum and plasma....
Medicine Products: